[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.240.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 1,510
Citations 0
Viewpoint
January 8, 2020

Tafamidis—A Pricey Therapy for a Not-So-Rare Condition

Author Affiliations
  • 1Meyers Primary Care Institute, a joint endeavor of University of Massachusetts Medical School, Fallon Health, and Reliant Medical Group, Worcester
  • 2Division of Geriatric Medicine, University of Massachusetts Medical School, Worcester
  • 3Center for Cardiac Amyloidosis, Division of Cardiology, Department of Internal Medicine, Columbia University Irving Medical Center, New York, New York
JAMA Cardiol. Published online January 8, 2020. doi:10.1001/jamacardio.2019.5233

On May 3, 2019, the US Food and Drug Administration (FDA) announced approval of the first treatments for cardiomyopathy caused by transthyretin amyloidosis (ATTR-CM). The FDA called the approvals of tafamidis meglumine and tafamidis “an important advancement” in the treatment of ATTR-CM, a “rare, debilitating, and often fatal disease.”1 Both of the approved formulations are lifelong treatments. The FDA granted tafamidis meglumine fast track, priority review, and breakthrough therapy designations and tafamidis meglumine and tafamidis received orphan drug designations. The approval of these novel therapies, their potential applicability to a patient population larger than recognized by the FDA, and their very high price present important challenges associated with access and affordability that will affect patients, clinicians, payers, and policymakers. This Viewpoint discusses these issues and presents recommendations that have heightened relevance as novel, very expensive therapies continue to emerge for previously untreatable conditions.

×